Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001178913-25-002335
Filing Date
2025-07-08
Accepted
2025-07-08 16:05:31
Documents
13
Period of Report
2025-07-08
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K zk2533427.htm   iXBRL 8-K/A 56212
  Complete submission text file 0001178913-25-002335.txt   232612

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250708.xsd EX-101.SCH 4740
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250708_def.xml EX-101.DEF 18263
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250708_lab.xml EX-101.LAB 27748
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250708_pre.xml EX-101.PRE 20505
16 EXTRACTED XBRL INSTANCE DOCUMENT zk2533427_htm.xml XML 6553
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-42253 | Film No.: 251111096
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)